These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

207 related items for PubMed ID: 3718170

  • 1. Longitudinal measurement of plasma homovanillic acid levels in schizophrenic patients. Correlation with psychosis and response to neuroleptic treatment.
    Pickar D, Labarca R, Doran AR, Wolkowitz OM, Roy A, Breier A, Linnoila M, Paul SM.
    Arch Gen Psychiatry; 1986 Jul; 43(7):669-76. PubMed ID: 3718170
    [Abstract] [Full Text] [Related]

  • 2. Neuroleptic-induced decrease in plasma homovanillic acid and antipsychotic activity in schizophrenic patients.
    Pickar D, Labarca R, Linnoila M, Roy A, Hommer D, Everett D, Paul SM.
    Science; 1984 Aug 31; 225(4665):954-7. PubMed ID: 6474162
    [Abstract] [Full Text] [Related]

  • 3. Changes in plasma homovanillic acid concentrations in schizophrenic patients following neuroleptic discontinuation.
    Davidson M, Kahn RS, Powchik P, Warne P, Losonczy MF, Kaminsky R, Apter S, Jaff S, Davis KL.
    Arch Gen Psychiatry; 1991 Jan 31; 48(1):73-6. PubMed ID: 1670618
    [Abstract] [Full Text] [Related]

  • 4. The acute effects of central- and peripheral-acting dopamine antagonists on plasma HVA in schizophrenic patients.
    Konicki PE, Owen RR, Litman RE, Pickar D.
    Life Sci; 1991 Jan 31; 48(14):1411-6. PubMed ID: 2008157
    [Abstract] [Full Text] [Related]

  • 5. Effects of neuroleptic treatment on symptoms of schizophrenia and plasma homovanillic acid concentrations.
    Davidson M, Kahn RS, Knott P, Kaminsky R, Cooper M, DuMont K, Apter S, Davis KL.
    Arch Gen Psychiatry; 1991 Oct 31; 48(10):910-3. PubMed ID: 1929760
    [Abstract] [Full Text] [Related]

  • 6. Longitudinal changes in symptoms and plasma homovanillic acid levels in chronically medicated schizophrenic patients.
    Suzuki E, Kanba S, Nibuya M, Adachi S, Sekiya U, Shintani F, Kinoshita N, Yagi G, Asai M.
    Biol Psychiatry; 1994 Nov 15; 36(10):654-61. PubMed ID: 7880934
    [Abstract] [Full Text] [Related]

  • 7. Circadian variation of plasma homovanillic acid levels is attenuated by fluphenazine in patients with schizophrenia.
    Doran AR, Labarca R, Wolkowitz OM, Roy A, Douillet P, Pickar D.
    Arch Gen Psychiatry; 1990 Jun 15; 47(6):558-63. PubMed ID: 2350208
    [Abstract] [Full Text] [Related]

  • 8. Plasma homovanillic acid in neuroleptic responsive and nonresponsive schizophrenics.
    Duncan E, Wolkin A, Angrist B, Sanfilipo M, Wieland S, Cooper TB, Rotrosen J.
    Biol Psychiatry; 1993 Oct 15; 34(8):523-8. PubMed ID: 8274579
    [Abstract] [Full Text] [Related]

  • 9. Perspectives on a time-dependent model of neuroleptic action.
    Pickar D.
    Schizophr Bull; 1988 Oct 15; 14(2):255-68. PubMed ID: 2904694
    [Abstract] [Full Text] [Related]

  • 10. Neuroleptics, dopamine, and schizophrenia.
    Pickar D.
    Psychiatr Clin North Am; 1986 Mar 15; 9(1):35-48. PubMed ID: 2870480
    [Abstract] [Full Text] [Related]

  • 11. Neuroleptic responsivity of negative and positive symptoms in schizophrenia.
    Breier A, Wolkowitz OM, Doran AR, Roy A, Boronow J, Hommer DW, Pickar D.
    Am J Psychiatry; 1987 Dec 15; 144(12):1549-55. PubMed ID: 3688278
    [Abstract] [Full Text] [Related]

  • 12. Plasma amine metabolites before and after withdrawal from neuroleptic treatment in chronic schizophrenic inpatients.
    Kirch DG, Jaskiw G, Linnoila M, Weinberger DR, Wyatt RJ.
    Psychiatry Res; 1988 Sep 15; 25(3):233-42. PubMed ID: 2903509
    [Abstract] [Full Text] [Related]

  • 13. Plasma prolactin and homovanillic acid as markers for psychopathology and abnormal movements during maintenance haloperidol treatment in male patients with schizophrenia.
    Newcomer JW, Riney SJ, Vinogradov S, Csernansky JG.
    Psychiatry Res; 1992 Mar 15; 41(3):191-202. PubMed ID: 1594706
    [Abstract] [Full Text] [Related]

  • 14. Effects of metabolic perturbation on plasma homovanillic acid in schizophrenia. Relationship to prefrontal cortex volume.
    Breier A, Davis OR, Buchanan RW, Moricle LA, Munson RC.
    Arch Gen Psychiatry; 1993 Jul 15; 50(7):541-50. PubMed ID: 8317948
    [Abstract] [Full Text] [Related]

  • 15. Plasma homovanillic acid differences in clinical subgroups of first episode schizophrenic patients.
    Baeza I, Castro-Fornieles J, Deulofeu R, de la Serna E, Goti J, Salvà J, Bernardo M.
    Psychiatry Res; 2009 Jul 30; 168(2):110-8. PubMed ID: 19501918
    [Abstract] [Full Text] [Related]

  • 16. The effect of neuroleptic discontinuation on psychopathology, involuntary movements, and biochemical measures in patients with persistent tardive dyskinesia.
    Glazer WM, Bowers MB, Charney DS, Heninger GR.
    Biol Psychiatry; 1989 Jul 30; 26(3):224-33. PubMed ID: 2568132
    [Abstract] [Full Text] [Related]

  • 17. Memory and plasma HVA changes in schizophrenia: are they episode markers?
    Gilbertson MW, Yao JK, van Kammen DP.
    Biol Psychiatry; 1994 Feb 01; 35(3):203-6. PubMed ID: 8173021
    [No Abstract] [Full Text] [Related]

  • 18. Plasma homovanillic acid as a predictor of response to neuroleptics.
    Davila R, Manero E, Zumarraga M, Andia I, Schweitzer JW, Friedhoff AJ.
    Arch Gen Psychiatry; 1988 Jun 01; 45(6):564-7. PubMed ID: 3377643
    [Abstract] [Full Text] [Related]

  • 19. Alprazolam augmentation of the antipsychotic effects of fluphenazine in schizophrenic patients. Preliminary results.
    Wolkowitz OM, Breier A, Doran A, Kelsoe J, Lucas P, Paul SM, Pickar D.
    Arch Gen Psychiatry; 1988 Jul 01; 45(7):664-71. PubMed ID: 3289524
    [Abstract] [Full Text] [Related]

  • 20. Genetic antecedents of dopamine dysfunction in schizophrenia.
    Amin F, Silverman JM, Siever LJ, Smith CJ, Knott PJ, Davis KL.
    Biol Psychiatry; 1999 May 01; 45(9):1143-50. PubMed ID: 10331106
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.